Merck, Astellas and Pfizer bring down the house with Keytruda-Padcev FDA nod in bladder cancer
Fierce Pharma
DECEMBER 18, 2023
The FDA has signed off on Astellas and Pfizer’s Padcev in combination with Merck’s Keytruda as a first-line treatment for bladder cancer.
Let's personalize your content